Publications 2018

Afshar-Oromieh A., Debus N., Uhrig M., Hope T.A., Evans M.J., Holland-Letz T., Giesel F.L., Kopka K., Hadaschik B., Kratochwil C., Haberkorn U.: Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer. Eur.J.Nucl.Med.Mol.Imaging 45 (12) 2045-2054, 2018.

Afshar-Oromieh A., Sattler L.P., Steiger K., Holland-Letz T., da Cunha M.L., Mier W., Neels O., Kopka K., Weichert W., Haberkorn U.: Tracer uptake in mediastinal and paraaortal thoracic lymph nodes as a potential pitfall in image interpretation of PSMA ligand PET/CT. Eur.J.Nucl.Med.Mol.Imag. 45 (7) 1179-1187, 2018.

Anwar H., Sachpekidis C., Winkler J., Kopp-Schneider A., Haberkorn U., Hassel J.C., Dimitrakopoulou-Strauss A.: Absolute number of new lesions on 18F-FDG PET/CT is more predictive of clinical response than SUV changes in metastatic melanoma patients receiving ipilimumab. Eur.J.Nucl.Med.Mol.Imag. 45 (3) 376-383, 2018.

Berberich A., Hielscher T., Kickingereder P., Winkler F., Druschler K., Riedemann L., Arzt M., Kessler T., Platten M., von D.A., Wick W., Sahm F., Bendszus M., Wick A.: Non-measurable speckled contrast-enhancing lesions appearing during course of disease are associated with IDH mutation in high-grade astrocytoma patients. Int.J.Radiat.Oncol.Biol.Phys. 102 (5) 1472-1480, 2018.

Bettinetti R., Kopp-Schneider A., Vignati D.A.L.: The European water-based environmental quality standard for pentachlorophenol is NOT protective of benthic organisms. Sci.Total Environ. 613-614 39-45, 2018.

Bochtler T., Merz M., Hielscher T., Granzow M., Hoffmann K., Kramer A., Raab M.S., Hillengass J., Seckinger A., Kimmich C., Dittrich T., Muller-Tidow C., Hose D., Goldschmidt H., Hegenbart U., Jauch A., Schonland S.O.: Cytogenetic intraclonal heterogeneity of plasma cell dyscrasia in AL amyloidosis as compared with multiple myeloma. Blood Adv. 2 (20) 2607-2618, 2018.

Bonekamp D., Kohl S., Wiesenfarth M., Schelb P., Radtke J.P., Gotz M., Kickingereder P., Yaqubi K., Hitthaler B., Gahlert N., Kuder T.A., Deister F., Freitag M., Hohenfellner M., Hadaschik B.A., Schlemmer H.P., Maier-Hein K.H.: Radiomic machine learning for characterization of prostate lesions with MRI: comparison to ADC values. Radiology 289 (1) 128-137, 2018.

Bormann F., Rodriguez-Paredes M., Lasitschka F., Edelmann D., Musch T., Benner A., Bergman Y., Dieter S.M., Ball C.R., Glimm H., Linhart H.G., Lyko F.: Cell-of-Origin DNA methylation signatures are maintained during colorectal carcinogenesis. Cell Rep. 23 (11) 3407-3418, 2018.

Brandelik S.C., Krzykalla J., Hielscher T., Hillengass J., Kloth J.K., Kauczor H.U., Weber M.A.: Fokale Läsionen in der Ganzkörper-MRT beim multiplen Myelom. Radiologe 58 (1) 72-78, 2018.

Bulut O.C., Haufe S., Hohenberger R., Hein M., Kratochwil C., Rathke H., Plinkert P.K., Baumann I., Holland-Letz T., Haberkorn U., Flechsig P.: Impact of sialendoscopy on improving health related quality of life in patients suffering from radioiodineinduced xerostomia. Nuklearmedizin 57 (4) 160-167, 2018.

Bunse L., Pusch S., Bunse T., Sahm F., Sanghvi K., Friedrich M., Alansary D., Sonner J.K., Green E., Deumelandt K., Kilian M., Neftel C., Uhlig S., Kessler T., von L.A., Berghoff A.S., Marsh K., Steadman M., Zhu D., Nicolay B., Wiestler B., Breckwoldt M.O., Al-Ali R., Karcher-Bausch S., Bozza M., Oezen I., Kramer M., Meyer J., Habel A., Eisel J., Poschet G., Weller M., Preusser M., Nadji-Ohl M., Thon N., Burger M.C., Harter P.N., Ratliff M., Harbottle R., Benner A., Schrimpf D., Okun J., Herold-Mende C., Turcan S., Kaulfuss S., Hess-Stumpp H., Bieback K., Cahill D.P., Plate K.H., Hanggi D., Dorsch M., Suva M.L., Niemeyer B.A., von D.A., Wick W., Platten M.: Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate. Nat.Med. 24 (8) 1192-1203, 2018.

Cao X., Tang Q., Holland-Letz T., Gundert M., Cuk K., Schott S., Heil J., Golatta M., Sohn C., Schneeweiss A., Burwinkel B.: Evaluation of promoter methylation of RASSF1A and ATM in peripheral blood of breast cancer patients and healthy control individuals. Int.J.Mol.Sci. 19 (3) E900, 2018.

Capper D., Jones D.T.W., Sill M., Hovestadt V., Schrimpf D., Sturm D., Koelsche C., Sahm F., Chavez L., Reuss D.E., Kratz A., Wefers A.K., Huang K., Pajtler K.W., Schweizer L., Stichel D., Olar A., Engel N.W., Lindenberg K., Harter P.N., Braczynski A.K., Plate K.H., Dohmen H., Garvalov B.K., Coras R., Holsken A., Hewer E., Bewerunge-Hudler M., Schick M., Fischer R., Beschorner R., Schittenhelm J., Staszewski O., Wani K., Varlet P., Pages M., Temming P., Lohmann D., Selt F., Witt H., Milde T., Witt O., Aronica E., Giangaspero F., Rushing E., Scheurlen W., Geisenberger C., Rodriguez F.J., Becker A., Preusser M., Haberler C., Bjerkvig R., Cryan J., Farrell M., Deckert M., Hench J., Frank S., Serrano J., Kannan K., Tsirigos A., Bruck W., Hofer S., Brehmer S., Seiz-Rosenhagen M., Hanggi D., Hans V., Rozsnoki S., Hansford J.R., Kohlhof P., Kristensen B.W., Lechner M., Lopes B., Mawrin C., Ketter R., Kulozik A., Khatib Z., Heppner F., Koch A., Jouvet A., Keohane C., Muhleisen H., Mueller W., Pohl U., Prinz M., Benner A., Zapatka M., Gottardo N.G., Driever P.H., Kramm C.M., Muller H.L., Rutkowski S., von H.K., Fruhwald M.C., Gnekow A., Fleischhack G., Tippelt S., Calaminus G., Monoranu C.M., Perry A., Jones C., Jacques T.S., Radlwimmer B., Gessi M., Pietsch T., Schramm J., Schackert G., Westphal M., Reifenberger G., Wesseling P., Weller M., Collins V.P., Blumcke I., Bendszus M., Debus J., Huang A., Jabado N., Northcott P.A., Paulus W., Gajjar A., Robinson G.W., Taylor M.D., Jaunmuktane Z., Ryzhova M., Platten M., Unterberg A., Wick W., Karajannis M.A., Mittelbronn M., Acker T., Hartmann C., Aldape K., Schuller U., Buslei R., Lichter P., Kool M., Herold-Mende C., Ellison D.W., Hasselblatt M., Snuderl M., Brandner S., Korshunov A., von D.A., Pfister S.M.: DNA methylation-based classification of central nervous system tumours. Nature 555 (7697) 469-474, 2018.

Cheng J., Holland-Letz T., Wallwiener M., Surowy H., Cuk K., Schott S., Trumpp A., Pantel K., Sohn C., Schneeweiss A., Burwinkel B.: Circulating free DNA integrity and concentration as independent prognostic markers in metastatic breast cancer. Breast Cancer Res.Treat. 169 (1) 69-82, 2018.

Dietrich S., Oles M., Lu j., Sellner L., Anders S., Velten B., Wu B., Hüllein J., da SIlva Liberio M., Walther T., Wagner L., Rabe S., Ghidelli-Disse S., Bantscheff M., Oles A.K., Stabicki M., Mock A., Oakes C.C., Wang S., Oppermann S., Lukas M., Kim V., Sill M., Benner A., Jauch A., Sutton L.A., Young E., Rosenquist R., Liu X., Jethwa A., Lee K.S., Lewis J., Putzker K., Lutz C., Rossi D., Mokhir A., Oellerich T., Zirlik K., Herling M., Nguyen-Khac F., Plass C., Andersson E., Mustjoki S., von Kalle C., Ho A.D., Hensel M., Dürig J., Ringshausen I., Zapatka M., Huber W., Zenz T.: Drug-perturbation-based stratification of blood cancer. J.Clin.Invest. 128 (1) 427-445, 2018.

Dürr C., Hanna B.S., Schulz A., Lucas F., Zucknick M., Benner A., Clear A., Ohl S., Öztürk S., Zenz T., Stilgenbauer S., Li-Weber M., Krammer P.H., Gribben J.G., Lichter P., Seiffert M.: TNF receptor signaling is a driver of chronic lymphocytic leukemia that can be therapeutically targeted by the flavonoid wogonin. Haematologica 103 (4) 688-697, 2018.

Edelmann D., Fokianos K., Pitsillou M.: An updated literature review of distance correlation and Its applications to time series. International Statistical Review 2018.

Flechsig P., Rastgoo R., Kratochwil C., Martin O., Holland-Letz T., Harms A., Kauczor H.U., Haberkorn U., Giesel F.L.: Impact of computer-aided CT and PET analysis on non-invasive T staging in patients with lung cancer and atelectasis. Mol.Imag.Biol. 20 (6) 1044-1052, 2018.

Flechsig P., Walker C., Kratochwil C., Konig L., Iagura A., Moltz J., Holland-Letz T., Kauczor H.U., Haberkorn U., Giesel F.L.: Role of CT density in PET/CT-based assessment of lymphoma. Mol.Imaging Biol. 20 (4) 641-649, 2018.

Goldschmidt H., Lokhorst H.M., Mai E.K., van der Holt B., Blau I.W., Zweegman S., Weisel K.C., Vellenga E., Pfreundschuh M., Kersten M.J., Scheid C., Crookewit S., Raymakers R., Hose D., Potamianou A., Jauch A., Hillengass J., Stevens-Kroef M., Raab M.S., Broijl A., Lindemann H.W., Bos G.M.J., Brossart P., van Marwijk-Kooy M., Ypma P., Duehrsen U., Schaafsma M., Bertsch U., Hielscher T., Jarari L., Salwender H., Sonneveld P.: Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial. Leukem. 32 (2) 383-390, 2018.

Habermehl C., Benner A., Kopp-Schneider A.: Addressing small sample size bias in multiple-biomarker trials: Inclusion of biomarker-negative patients and Firth correction. Biometr.J. 60 (2) 275-287, 2018.

Hagens C.v., Walter-Sack I., Göckenjan M., Storch-Hagenlocher B., Sertel S., Elsässer M., Remppis B.A., Munzinger J., Edler L., Efferth T., Schneeweiss A., Strowitzki T.: Long-term add-on therapy (compassionate use) with oral artesunate in patients with metastatic breast cancer after participating in a phase I study (ARTIC M33/2). Phytomed. 54 (epub) 140-148, 2018.

Haselmann V., Gebhardt C., Brechtel I., Duda A., Czerwinski C., Sucker A., Holland-Letz T., Utikal J., Schadendorf D., Neumaier M.: Liquid profiling of circulating tumor DNA in plasma of melanoma patients for companion diagnostics and monitoring of BRAF Inhibitor therapy. Clin.Chem. 64 (5) 830-842, 2018.

Holland-Letz T., Gunkel N., Amtmann E., Kopp-Schneider A.: Parametric modeling and optimal experimental designs for estimating isobolograms for drug interactions in toxicology. J.Biopharm.Stat. 28 (4) 763-777, 2018.

Ishaque N., Abba M.L., Hauser C., Patil N., Paramasivam N., Hübschmann D., Leupold J.H., Balasubramanian G.P., Kleinheinz K., Toprak U.H., Hutter B., Benner A., Shavinskaya A., Zhou C., Gu Z., Kerssemakers J., Marx A., Moniuszko M., Kozlowski M., Reszec J., Niklinski J., Eils J., Schlesner M., Eils R., Brors B., Allgayer H.: Whole genome sequencing puts forward hypotheses on metastasis evolution and therapy in colorectal cancer. Nat.Commun. 9 (1) 4782, 2018.

Janikovits J., Müller M., Krzykalla J., Körner S., Echterdiek F., Lahrmann B., Grabe N., Schneider M., Benner A., von Knebel-Döberitz M., Kloor M.: High numbers of PDCD1 (PD-1)-positive T cells and B2M mutations in microsatellite-unstable colorectal cancer. OncoImmunol. 7 (2) e1390640, 2018.

Karimian-Jazi K., Wildemann B., Diem R., Schwarz D., Hielscher T., Wick W., Bendszus M., Breckwoldt M.O.: Gd contrast administration is dispensable in patients with MS without new T2 lesions on follow-up MRI. Neurol.Neuroimmunol.Neuroinflamm. 5 (5) e480, 2018.

Katz L.M., Hielscher T., Liechty B., Silverman J., Zagzag D., Sen R., Wu P., Golfinos J.G., Reuss D., Neidert M.C., Wirsching H.G., Baumgarten P., Herold-Mende C., Wick W., Harter P.N., Weller M., von D.A., Snuderl M., Sen C., Sahm F.: Loss of histone H3K27me3 identifies a subset of meningiomas with increased risk of recurrence. Acta Neuropathol. 135 (6) 955-963, 2018.

Kesch C., Radtke J.P., Wintsche A., Wiesenfarth M., Luttje M., Gasch C., Dieffenbacher S., Pecqueux C., Teber D., Hatiboglu G., Nyarangi-Dix J., Simpfendörfer T., Schönberg G., Dimitrakopoulou-Strauss A., Freitag M., Dünsing A., Grüllich C., Jäger D., Götz M., Grabe N., Schweiger M.R., Pahernik S., Perner S., Herpel E., Roth W., Wieczorek K., Maier-Hein K., Debus J., Haberkorn U., Giesel F., Galle J., Hadaschik B., Schlemmer H.P., Hohenfellner M., Bonekamp D., Sültmann H., Dünsing S.: Correlation between genomic index lesions and mpMRI and (68)Ga-PSMA-PET/CT imaging features in primary prostate cancer. Sci.Rep. 8 (1) 16708, 2018.

Kesch C., Radtke J.P., Wintsche A., Wiesenfarth M., Luttje M., Gasch C., Dieffenbacher S., Teber D., Hatiboglu G., Nyarangi-Dix J., Simpfendörfer T., Dimitrakopoulou-Strauss A., Freitag M.T., Dünsing A., Grüllich C., Gölz M., Jäger D., Grabe N., Schweiger M.R., Giesel F.L., Roth W., Perner S., Galle J., Maier-Hein K., Hadaschik B.A., Schlemmer H.P., Hohenfellner M., Bonekamp D., Sültmann H., Dünsing S.: PD47-04 correlation between genomic index lesions, multi-parametric MRI and 68Ga-PSMA PET-CT imaging features in primary prostate cancer. J.Urol. 199 (4 Suppl.) e898, 2018.

Kickingereder P., Neuberger U., Bonekamp D., Piechotta P.L., Götz M., Wick A., Sill M., Kratz A., Shinohara R.T., Jones D.T.W., Radbruch A., Muschelli J., Unterberg A., Debus J., Schlemmer H.P., Herold-Mende C., Pfister S., von Deimling A., Wick W., Capper D., Maier-Hein K.H., Bendszus M.: Radiomic subtyping improves disease stratification beyond key molecular, clinical and standard imaging characteristics in patients with glioblastoma. Neuro-Oncol. 20 (6) 848-857, 2018.

Kopp-Schneider A., Wiesenfarth M., Witt R., Edelmann D., Witt O., Abel U.: Monitoring futility and efficacy in phase II trials with Bayesian posterior distributions. A calibration approach. Biometr.J. 2018.

Kopp-Schneider A., Werft W.: Grundlagen der Statistik. In: W.Schlegel, C.P.Karger, O.Jäkel (Eds), Medizinische Physik. Springer Spektrum, Berlin, Heidelberg, 2018, pp.37-64.

Krilaviciute A., Leja M., Kopp-Schneider A., Barash O., Khatib S., Amal H., Broza Y., Polaka I., Parshutin S., Rudule A., Haick H., Brenner H.: Associations of diet and lifestyle factors with common volatile organic compounds in exhaled breath of average-risk individuals. J.Breath Res. (epub) , 2018.

Lehners N., Becker N., Benner A., Pritsch M., Löpprich M., Mai E.K., Hillengass J., Goldschmidt H., Raab M.S.: Analysis of long-term survival in multiple myeloma after first-line autologous stem cell transplantation: impact of clinical risk factors and sustained response. Cancer Med. 7 (2) 307-316, 2018.

Limonciel A., van Breda S.G., Jiang X., Tredwell G.D., Wilmes A., Aschauer L., Siskos A.P., Sachinidis A., Keun H.C., Kopp-Schneider A., de Kok T.M., Kleinjans J.C.S., Jennings P.: Persistence of epigenomic effects after recovery from repeated treatment with two nephrocarcinogens. Front Genet. 9 558, 2018.

Maatouk I., He S., Becker N., Hummel M., Hemmer S., Hillengass M., Goldschmidt H., Hartmann M., Schellberg D., Herzog W., Hillengass J.: Association of resilience with health-related quality of life and depression in multiple myeloma and its precursors: results of a German cross-sectional study. BMJ Open 8 (7) e021376, 2018.

Mai E.K., Haas E.M., Lücke S., Lopprich M., Kunz C., Pritsch M., Knaup-Gregori P., Raab M.S., Schlenzka J., Bertsch U., Hillengass J., Goldschmidt H.: A systematic classification of death causes in multiple myeloma. Blood Cancer J. 8 (3) 30, 2018.

Maier-Hein L., Eisenmann M., Reinke A., Onogur S., Stankovic M., Scholz P., Arbel T., Bogunovic H., Bradley A.P., Carass A., Feldmann C., Frangi A.F., Full P.M., van Ginneken B., Hanbury A., Honauer K., Kozubek M., Landmann B.A., März K., Maier O., Maier-Hein K., Menze B.H., Müller H., Neher P.F., Niessen W., Rajpoot N., Sharp G.C., Sirinukunwattana K., Speidel S., Stock C., Stoyanov D., Taha A.A., van der Sommen F., Wang C.W., Weber M.A., Zheng G., Jannin P., Kopp-Schneider A.: Why rankings of biomedical image analysis competitions should be interpreted with care. Nat.Commun. 9 5217, 2018.

Merz M., Jauch A., Hielscher T., Bochtler T., Schönland S.O., Seckinger A., Hose D., Bertsch U., Neben K., Raab M.S., Hillengass J., Salwender H., Blau I.W., Lindemann H.W., Schmidt-Wolf I.G.H., Scheid C., Hänel M., Weisel K.C., Goldschmidt H.: Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myeloma. Blood Adv. 2 (1) 1-9, 2018.

Merz M., Hielscher T., Hoffmann K., Seckinger A., Hose D., Raab M.S., Hillengass J., Jauch A., Goldschmidt H.: Cytogenetic abnormalities in monoclonal gammopathy of undetermined significance. Leukem. 32 (12) 2717-2719, 2018.

Michels J., Becker N., Suciu S., Kaiser I., Benner A., Kosaloglu-Yalcin Z., Agoussi S., Halama N., Pawlita M., Waterboer T., Eichmuller S.B., Jager D., Eggermont A.M.M., Zornig I.: Multiplex bead-based measurement of humoral immune responses against tumor-associated antigens in stage II melanoma patients of the EORTC18961 trial. OncoImmunol. 7 (6) e1428157, 2018.

Mosebach J., Shah S., Delorme S., Hielscher T., Goldschmidt H., Schlemmer H.P., Schönland S.O., Hegenbart U., Hillengass J.: Prognostic significance of tumor burden assessed by whole-body magnetic resonance imaging in multiple myeloma patients treated with allogeneic stem cell transplantation. Haematologica 103 (2) 336-343, 2018.

Nyarangi-Dix J., Wiesenfarth M., Bonekamp D., Hitthaler B., Schutz V., Dieffenbacher S., Mueller-Wolf M., Roth W., Stenzinger A., Duensing S., Roethke M., Teber D., Schlemmer H.P., Hohenfellner M., Radtke J.P.: Combined clinical parameters and multiparametric magnetic resonance imaging for the prediction of extraprostatic disease. A risk model for patient-tailored risk stratification when planning radical prostatectomy. Eur.Urol.Focus 2018.

Nyarangi-Dix J.N., Tichy D., Hatiboglu G., Pahernik S., Tosev G., Hohenfellner M.: Complete bladder neck preservation promotes long-term post-prostatectomy continence without compromising midterm oncological outcome: analysis of a randomised controlled cohort. World J.Urol. 36 (3) 349-355, 2018.

Ose J., Botma A., Balavarca Y., Buck K., Scherer D., Habermann N., Beyerle J., Pfutze K., Seibold P., Kap E.J., Benner A., Jansen L., Butterbach K., Hoffmeister M., Brenner H., Ulrich A., Schneider M., Chang-Claude J., Burwinkel B., Ulrich C.M.: Pathway analysis of genetic variants in folate-mediated one-carbon metabolism-related genes and survival in a prospectively followed cohort of colorectal cancer patients Cancer Med. 7 (7) 2797-2807, 2018.

Paschka P., Schlenk R.F., Weber D., Benner A., Bullinger L., Heuser M., Gaidzik V.I., Thol F., Agrawal M., Teleanu V., Lubbert M., Fiedler W., Radsak M., Krauter J., Horst H.A., Greil R., Mayer K., Kundgen A., Martens U., Heil G., Salih H.R., Hertenstein B., Schwanen C., Wulf G., Lange E., Pfreundschuh M., Ringhoffer M., Girschikofsky M., Heinicke T., Kraemer D., Gohring G., Ganser A., Dohner K., Dohner H.: Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia-results of the AMLSG 11-08 trial. Leukem. 32 (7) 1621-1630, 2018.

Qian J., Tikk K., Werner S., Balavarca Y., Saadati M., Hechtner M., Brenner H.: Biomarker discovery study of inflammatory proteins for colorectal cancer early detection demonstrated importance of screening setting validation. J.Clin.Epidemiol. 104 24-34, 2018.

Rathke H., Afshar-Oromieh A., Giesel F.L., Kremer C., Flechsig P., Haufe S., Mier W., Holland-Letz T., de Bucourt M., Armor T., Babich J., Haberkorn U., Kratochwil C.: Intra-individual comparison of Tc-99m-MDP bone scan and the PSMA-ligand Tc-99m-MIP-1427 in patients with osseous metastasized prostate cancer. J.Nucl.Med. 59 (9) 1373-1379, 2018.

Rauscher B., Heigwer F., Henkel L., Hielscher T., Voloshanenko O., Boutros M.: Toward an integrated map of genetic interactions in cancer cells. Mol.Syst.Biol. 14 (2) e7656, 2018.

Rodrigues R.M., Kollipara L., Chaudhari U., Sachinidis A., Zahedi R.P., Sickmann A., Kopp-Schneider A., Jiang X., Keun H., Hengstler J., Oorts M., Annaert P., Hoeben E., Gijbels E., De K.J., Vanhaecke T., Rogiers V., Vinken M.: Omics-based responses induced by bosentan in human hepatoma HepaRG cell cultures. Arch.Toxicol. 92 (6) 1939-1952, 2018.

Ross T., Zimmerer D., Vemuri A., Isensee F., Wiesenfarth M., Bodenstedt S., Both F., Kessler P., Wagner M., Müller B., Kenngott H., Speidel S., Kopp-Schneider A., Maier-Hein K., Maier-Hein L.: Exploiting the potential of unlabeled endoscopic video data with self-supervised learning. Int.J.Comp.Assist.Radiol.SUrg. 13 (6) 925-933, 2018.

Röhrich M., Huang K., Schrimpf D., Albert N.L., Hielscher T., von D.A., Schuller U., Dimitrakopoulou-Strauss A., Haberkorn U.: Integrated analysis of dynamic FET PET/CT parameters, histology, and methylation profiling of 44 gliomas. Eur.J.Nucl.Med.Mol.Imaging 45 (9) 1573-1584, 2018.

Rölle A., Meyer M., Calderazzo S., Jäger D., Momburg F.: Distinct HLA-E peptide complexes modify antibody-driven effector functions of adaptive NK cells. Cell Rep. 24 (8) 1967-1976, 2018.

Saadati M., Beyersmann J., Kopp-Schneider A., Benner A.: Prediction accuracy and variable selection for penalized cause-specific hazards models. Biometr.J. 60 (2) 288-306, 2018.

Sachpekidis C., Anwar H., Winkler J., Kopp-Schneider A., Larribere L., Haberkorn U., Hassel J.C., Dimitrakopoulou-Strauss A.: The role of interim 18F-FDG PET/CT in prediction of response to ipilimumab treatment in metastatic melanoma. Eur.J.Nucl.Med.Mol.Imag. 45 (8) 1289-1296, 2018.

Sachpekidis C., Anwar H., Winkler J.K., Kopp-Schneider A., Larribere L., Haberkorn U., Hassel J.C., Dimitrakopoulou-Strauss A.: Longitudinal studies of the (18)F-FDG kinetics after ipilimumab treatment in metastatic melanoma patients based on dynamic FDG PET/CT. Cancer Immunol.Immunother. 67 (8) 1261-1270, 2018.

Sachpekidis C., Bäumer P., Kopka K., Hadaschik B.A., Hohenfellner M., Kopp-Schneider A., Haberkorn U., Dimitrakopoulou-Strauss A.: 68Ga-PSMA PET/CT in the evaluation of bone metastases in prostate cancer. Eur.J.Nucl.Med.Mol.Imag. 45 (6) 904-912, 2018.

Sachpekidis C., Goldschmidt H., Kopka K., Kopp-Schneider A., Dimitrakopoulou-Strauss A.: Assessment of glucose metabolism and cellular proliferation in multiple myeloma: a first report on combined F-18-FDG and F-18-FLT PET/CT imaging. EJNMMI Research 8 (1) 28, 2018.

Schröder L., Wichmann G., Willner M., Michel A., Wiesenfarth M., Flechtenmacher C., Gradistanac T., Pawlita M., Dietz A., Waterboer T., Holzinger D.: Antibodies against human papillomaviruses as diagnostic and prognostic biomarker in patients with neck squamous cell carcinoma from unknown primary. Int.J.Cancer 142 1361-1368, 2018.

Sievers P., Stichel D., Hielscher T., Schrimpf D., Reinhardt A., Wefers A.K., Reuss D., Jones D.T.W., Bewerunge-Hudler M., Hartmann C., Baumgarten P., Wirsching H.G., Winther-Kristensen B., Brokinkel B., Ketter R., Idoate Gastearena M.A., Lamszus K., Seiz-Rosenhagen M., Mawrin C., Harter P.N., Felsberg J., Hanggi D., Herold-Mende C., Berghoff A.S., Weller M., Pfister S.M., Wick W., Reifenberger G., Preusser M., von D.A., Sahm F.: Chordoid meningiomas can be sub-stratified into prognostically distinct DNA methylation classes and are enriched for heterozygous deletions of chromosomal arm 2p. Acta Neuropathol. 136 (6) 975-978, 2018.

Stoyan D., Pommerening A., Hummel M., Kopp-Schneider A.: Multiple-rater kappas for binary data: Models and interpretation. Biometr.J. 60 (2) 381-394, 2018.

Tichy D., Pickl J.M.A., Benner A., Sültmann H.: Experimental design and data analysis of Ago-RIP-Seq experiments for the identification of microRNA targets. Brief.Bioinformat. 19 (5) 918-929, 2018.

Tikk K., Czock D., Haefeli W.E., Kopp-Schneider A., Brenner H.: Clinical trial protocol of the ASTER trial: a double-blind, randomized, placebo-controlled phase III trial evaluating the use of acetylsalicylic acid (ASA) for enhanced early detection of colorectal neoplasms. BMC Cancer 18 (1) 914, 2018.

Twardella D., Geiss K., Radespiel-Tröger M., Benner A., Ficker J.H., Meyer M.: [Trends in incidence of lung cancer according to histological subtype among men and women in Germany : Analysis of cancer registry data with the application of multiple imputation techniques]. Bundesgesundheitsbl.Gesundheitsforsch.Gesundheitsschutz 61 (1) 20-31, 2018.

Wang L., Ni M., Huckelhoven-Krauss A., Sellner L., Hoffmann J.M., Neuber B., Luft T., Hegenbart U., Schonland S., Kleist C., Sill M., Chen B.A., Wuchter P., Eckstein V., Kruger W., Hilgendorf I., Yerushalmi R., Nagler A., Müller-Tidow C., Ho A.D., Dreger P., Schmitt M., Schmitt A.: Modulation of B cells and homing marker on NK Cells through extracorporeal photopheresis in patients with steroid-refractory/resistant graft-vs.-host disease without hampering anti-viral/anti-leukemic effects. Front Immunol. 9 2207, 2018.

Wei G., Kehl T., Bao Q., Benner A., Lei J., Löchelt M.: The chromatin binding domain, including the QPQRYG motif, of feline foamy virus Gag is required for viral DNA integration and nuclear accumulation of Gag and the viral genome. Virol. 524 56-58, 2018.

Wennmann M., Kintzele L., Piraud M., Menze B.H., Hielscher T., Hofmanninger J., Wagner B., Kauczor H.U., Merz M., Hillengass J., Langs G., Weber M.A.: Volumetry based biomarker speed of growth: Quantifying the change of total tumor volume in whole-body magnetic resonance imaging over time improves risk stratification of smoldering multiple myeloma patients. Oncotarget. 9 (38) 25254-25264, 2018.

Wirthschaft P., Bode J., Simon A.E.M., Hoffmann E., van L.R., Kruwel T., Dietrich F., Bucher D., Hahn A., Sahm F., Breckwoldt M.O., Kurz F.T., Hielscher T., Fischer B., Dross N., Ruiz de A.C., von D.A., Herold-Mende C., Plass C., Boulant S., Wiestler B., Reifenberger G., Lichter P., Wick W., Tews B.: A PRDX1-p38alpha heterodimer amplifies MET-driven invasion of IDH-wildtype and IDH-mutant gliomas. Int.J.Cancer 143 (5) 1176-1187, 2018.

Wolf C., Garding A., Filarsky K., Bahio J., Robrecht S., Becker N., Zucknick M., Rouhi A., Weigel A., Claus R., Weichenhan D., Eichhorst B., Fischer K., Hallek M., Küchenbauer F., Plass C., Döhner H., Stilgenbauer S., Lichter P., Mertens D.: NFATC1 activation by DNA hypomethylation in chronic lymphocytic leukemia correlates with clinical staging and can be inhibited by ibrutinib. Int.J.Cancer 142 (2) 322-333, 2018.

Wunsche P., Eckert E.S.P., Holland-Letz T., Paruzynski A., Hotz-Wagenblatt A., Fronza R., Rath T., Gil-Farina I., Schmidt M., von K.C., Klein C., Ball C.R., Herbst F., Glimm H.: Mapping active gene-regulatory regions in human repopulating long-term HSCs. Cell Stem Cell 23 (1) 132-146, 2018.

Zgheib E., Limonciel A., Jiang X.Q., Wilmes A., Wink S., van de Water B., Kopp-Schneider A., Bois F., Jennings P.: Investigation of Nrf2, AhR and ATF4 activation in toxicogenomic databases. Front.Genet. 9 429, 2018.